Tag Archives: Immunotherapy for Cancer

New T Cell Tracking May Improve Immunotherapy Treatments

Another Step in Stopping Cancer
New T Cell Tracking May Improve Immunotherapy Treatments

T cells are in the front line of your immune system, multiplying rapidly to attack invading cells throughout your body. Immunotherapy for cancer took a big step forward with a study that found ways to track T cells in order to harness their specific tumor-fighting abilities.

Finding a Needle in a Haystack

Adoptive T cell transfer is a method of treatment in which T cells are harvested from a patient’s body and “groomed” to target cancer cells. They were then multiplied and placed back in the patient’s system where they could attack the tumor.

Unfortunately, there are a couple of roadblocks to this process. It’s difficult to know which of the thousands of different types of T cells are most effective against cancer, and cloning the cells can dilute or alter the tumor-killing properties of the originals.

Solving the Identification Problem

Researchers at Seattle’s Fred Hutchinson Cancer Research Center have discovered a process to help solve the former problem. A method called high throughput T cell receptor sequencing allowed the scientists to tag each T cell receptor with a “barcode,” enabling them to be tracked throughout the body.

The team gained valuable data when they applied the method to 10 patients with metastatic melanoma. Trials are now underway in search of more effective ways to extract and multiply T cells.

Immunotherapy for Cancer: Boosting Your Body’s Natural Defenses

For decades, Issels® has been a pioneer in the use of vaccines, NK cells and other non-toxic immunotherapy for cancer treatments. Visit our website to learn more about our individually tailored programs.

Dr. Josef M. Issels Predicted the Future of Immunotherapy

Dr. Josef M. Issels, Our Founder
Dr. Josef M. Issels, Our Founder

Over the last few years, immunotherapy for cancer has become increasingly embraced by the medical community. But it was more than 20 years ago when our founder, Dr. Josef M. Issels, predicted the future of immunotherapy as an integrative and interdisciplinary approach.

A Groundbreaking Approach to Cancer Treatment

In a practice that spanned more than 40 years, Dr. Issels conducted research involving patients in the end stages of cancer, most of whom had exhausted all traditional methods of treatment. Results led to his pioneering a “holistic concept” of fighting cancer.

While traditional treatments focused on cancer as a disease unto itself, Dr. Issels believed it was a symptom of a larger disease affecting the entire person, body and mind. In such cases, the immune system is unable to perform its usual duties of defending against chronic development of malignant cells.

The breakdown of normal immune system functions centers on T-cells including Natural Killer (NK) Cells, which have the job of detecting and identifying foreign substances that enter the body. Without this normal barrier, malignant cells are free to multiply and form tumors.

Immunotherapy: An Integrative Method

Dr. Issels’ approach went beyond destruction and removal of tumors to address the main underlying causes of malignant cell development and immune system suppression in order to achieve long-term tumor remissions.

Traditional methods such as radiation and chemotherapy merely focus on the cancer cells and tumors. When they become part of an integrative treatment, including non-toxic immunotherapy, they can achieve better results with fewer side effects.

State-of-the-Art Immunotherapy for Cancer at Issels®

Our highly personalized non-toxic immunotherapy programs include Cancer Vaccines, Natural Killer (NK) Cells, Lymphokine-Activated Killer (LAK) Cells and Cytokines.

Contact us today to learn more about why immunotherapy for cancer is one of the hottest topics in modern healthcare.

Highlighting Natural Killer Cell Activation through the Issels Immunotherapy Protocol

Worker in a lab
NK Cells and Immunotherapy for Cancer

Natural Killer (NK) cells may sound scary, but they play a valuable role in immunotherapy for cancer. Boosting NK cell levels helps the immune system mount a strong response in order to eliminate tumors.

How Natural Killer Cells Work

When cancer is diagnosed early, treatment has a good success rate. Cases of late-stage cancer are more difficult to treat because the tumor cells have often begun metastasizing throughout the body.

This is where NK cells come in. They fight tumors as well as metastasized cancer cells through production of proteins known as cytokines. In addition, NK cells are so-called because of their capacity to quickly attack foreign bodies without the activation of antibodies.

Another valuable benefit of NK cells is their function in mediating anti-tumor immunity. Studies have shown that mice with reduced levels of NK cells have lowered resistance to metastases and RMA tumor outgrowth.

The Effect of Immunotherapy on NK Cell Levels

An analysis of NK cell counts was done on 129 patients who had gone through the Issels® treatment program. The group of patients ranged across all four Stage classifications and a wide variety of types of tumors.

Each patient’s individual protocols included non-toxic treatments such as immune-stimulants, autohemotherapy, oxidative therapy, enzymatic therapy, phytotherapy, amino acids, detoxification strategies, dietary and life-style changes, as well as emotional support. After approximately three weeks, the group showed an average 48 percent increase in absolute NK cell levels per individual.

Issels®: A Trailblazer in Immunotherapy for Cancer

Our clinic was established to carry on the groundbreaking work of our founder, Dr. Josef M Issels, in the field of immunotherapy for cancer. Contact us for more information about cancer vaccines and other personally tailored treatment programs.

Reader Reviews of “Cancer: a Second Opinion” by Dr. Josef M. Issels

Josef M. Issels, Our Founder
Josef M. Issels, Our Founder

“Every second of every day, a man, woman or child dies of cancer.” That is the opening line of Cancer: A Second Opinion, written by Dr. Josef M. Issels, founder and namesake of our immunotherapy for cancer clinic. It also sums up why he felt the need to share his valuable work with the rest of the world.

“A General Disease of the Whole Body”

The medical community has traditionally viewed cancer as a localized disease and focused treatment on the tumor itself. Dr. Issels put forth the idea that cancer is actually the symptom of a generalized disease affecting the entire body.

This concept formed the basis of Dr. Issels’ groundbreaking work developing integrative immunotherapy for cancer treatments. While acknowledging that methods such as surgery and radiotherapy are necessary tools, Dr. Issels focused on treatments that fight the cause of cancer by boosting the immune system, the body’s natural line of defense.

The Public Responds

Cancer: A Second Opinion has achieved a five-star rating on Amazon. Here’s what some readers had to say in their reviews:

  • “Perhaps the most important book written on cancer in the twentieth century.”
  • “This book is for fighters.”
  • “When confronted with cancer I wanted to read more, and this was a great book for info. Would suggest it to anyone dealing with this.”

Issels®: A Pioneer in Immunotherapy for Cancer

Cancer vaccines, NK cells and hyperthermia are some of the non-toxic, innovative treatments used at our Issels® clinic. Visit our website to learn more about Dr. Issels and how we are carrying his legacy forward.

Medical University of South Carolina’s Antibody Treatment Research Holds Promise

Immunotherapy for Cancer
Immunotherapy for Cancer using Antibody Treatment

Researchers continue to make strides in discovering new cancer immunotherapy methods that help doctors successfully target tumor cells. As revealed in a recently published report, a team of scientists at the Medical University of South Carolina (MUSC) have created a promising antibody-based therapy using a specific diagnostic marker known as GARP.

When Immune Cells Fail

Numerous studies have focused on TGF-beta, which is a protein used by regulatory T-cells (Tregs) to direct immune cells away from healthy cells. Malignant tumors get around this by releasing vast amounts of TGF-beta, essentially hijacking Tregs and causing them to suppress immune cell activity against the cancer cells.

GARP is the only known receptor that lets TGF-beta dock on cell surfaces. The MUSC team set out to determine whether GARP was the means by which tumor cells were able to harness TGF-beta.

Is GARP the Key to Activating Tregs?

After finding that GARP levels were higher in certain types of tumors, the team conducted a test in which they removed the GARP gene from mice with mammary tumors. As a result, the tumors grew more slowly and there was little metastasis to the lungs.

The MUSC team then used human GARP in mice to develop antibodies. Their hope is that in the future, cancer immunotherapy in conjunction with GARP antibodies will result in more effective treatment for breast cancer.

State-of-the-Art Cancer Immunotherapy at Issels®

For decades, Issels® has been the leader in non-toxic integrative cancer treatments that boost your own immune system’s ability to fight tumors. Contact us today to learn more about the Issels® difference.

 

The Issels Story – a Focus on Immunotherapy

Another Step in Stopping Cancer
We Are Dedicated to Stopping Cancer

Immunotherapy for cancer has been a hot topic in the news lately, but the methods are far from new. Our founder, Dr. Josef Issels, was a pioneer in the field of integrative immuno-oncology dating back to the mid-20th century.

Josef Issels: A Life Dedicated to Fighting Cancer

Dr. Issels began his trailblazing path in 1948, conducting extensive research on the causes of cancer while working in his native Germany. His studies focused on the role of the immune system in fighting cancer as well as microbial aspects of the disease.

In 1951, Dr. Issels founded the first hospital in the world devoted exclusively to integrative immunotherapy, focusing on patients for whom traditional treatments had failed. The revolutionary Issels program went above and beyond standard tumor-centered treatments, and many patients experienced partial or total long-term remission.

As the integrative procedures developed by Dr. Issels continued to generate successful results, the hospital added 35 beds in 1970 for a total of 125. The scope of research also expanded to include programs such as vaccines, hypothermia and mycoplasma.

After Dr. Issels retired, he brought his innovative immuno-oncology programs to America. Since his death in 1998, his wife, Ilse Marie, has continued his work alongside their sons, Christian and Hellmut. The trio has maintained the same dedication and level of excellence set forth by Dr. Issels.

Issels® Continues to Lead the Way in Immunotherapy for Cancer

Nearly 70 years later, our patients continue to benefit from the foresight and tireless work of Josef Issels. Contact us for more information about our state-of-the-art programs that are personally tailored to meet each patient’s specific needs.